Highland Capital Management LLC Sells 1,540 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Highland Capital Management LLC lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,450 shares of the specialty pharmaceutical company’s stock after selling 1,540 shares during the quarter. Highland Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Kovack Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 88.8% in the 1st quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after purchasing an additional 26,628 shares in the last quarter. John G Ullman & Associates Inc. bought a new position in shares of Jazz Pharmaceuticals during the first quarter valued at about $3,631,000. Swedbank AB purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $106,936,000. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after buying an additional 84,941 shares during the period. Finally, LSV Asset Management lifted its stake in shares of Jazz Pharmaceuticals by 1.6% in the 1st quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after acquiring an additional 37,631 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the topic of several recent research reports. UBS Group decreased their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Finally, Robert W. Baird lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.43.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ:JAZZ opened at $109.55 on Friday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.48. The stock’s fifty day moving average price is $110.98 and its 200-day moving average price is $109.57. The company has a market cap of $6.76 billion, a P/E ratio of 18.82, a PEG ratio of 1.41 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.06 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.